Rein Therapeutics Inc. (NASDAQ:RNTX) Stock Now Rated “Hold” by Wall Street Brokerages

Rein Therapeutics Inc. (NASDAQ:RNTX) has received an average recommendation of “Hold” from the four brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $6.00.

A number of brokerages recently commented on RNTX. Weiss Ratings cut shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. HC Wainwright reiterated a “buy” rating on shares of Rein Therapeutics in a research note on Tuesday, August 18th. Wall Street Zen upgraded Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Maxim Group initiated coverage on Rein Therapeutics in a report on Monday, July 20th. They issued a “buy” rating and a $4.00 price target for the company.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Chicago Partners Investment Group LLC grew its holdings in Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after buying an additional 10,000 shares in the last quarter. Gagnon Securities LLC lifted its holdings in shares of Rein Therapeutics by 5.0% in the fourth quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock worth $279,000 after buying an additional 11,528 shares in the last quarter. Sequoia Financial Advisors LLC bought a new position in shares of Rein Therapeutics in the second quarter valued at approximately $260,000. Sigma Planning Corp grew its stake in Rein Therapeutics by 41.0% during the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock valued at $453,000 after acquiring an additional 101,400 shares in the last quarter. Finally, Velan Capital Investment Management LP bought a new stake in Rein Therapeutics during the 2nd quarter worth approximately $1,768,000. Institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Stock Performance

Shares of Rein Therapeutics stock opened at $0.80 on Friday. Rein Therapeutics has a 52-week low of $0.69 and a 52-week high of $2.18. The stock’s 50-day simple moving average is $0.79 and its 200 day simple moving average is $1.03. The stock has a market capitalization of $69.08 million, a P/E ratio of -0.47 and a beta of 1.35.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. Equities research analysts forecast that Rein Therapeutics will post -0.47 EPS for the current fiscal year.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for serious diseases with significant unmet medical needs. The company’s research and development activities are centered on fibrotic diseases, in which excessive scar tissue can impair the function of organs and lead to progressive illness.

Rein Therapeutics’ lead investigational program is RNTX-001, an experimental therapy being developed for pulmonary fibrosis and potentially other fibrotic conditions.